A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).

Dagmar Wilsmann-Theis Christian KromerS GerdesC LinkerN MagnoloR SabatKristian ReichR Mössner

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)

Patients with PPP treated with apremilast showed benefit both in objective and subjective disease parameters. Apremilast should be investigated further in this difficult-to-treat skin condition. EudraCT number: 2016-005122-11.

Keyphrases

open label
clinical trial
study protocol
squamous cell carcinoma
wound healing
phase ii
physical activity
depressive symptoms
atomic force microscopy
radiation therapy
sleep quality
placebo controlled